BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 25490678)

  • 1. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
    Deb S; Wong SQ; Li J; Do H; Weiss J; Byrne D; Chakrabarti A; Bosma T; ; Fellowes A; Dobrovic A; Fox SB
    Br J Cancer; 2014 Dec; 111(12):2351-60. PubMed ID: 25490678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
    Deb S; Do H; Byrne D; Jene N; ; Dobrovic A; Fox SB
    Breast Cancer Res; 2013; 15(4):R69. PubMed ID: 23971979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.
    Deb S; Jene N; ; Fox SB
    BMC Cancer; 2012 Nov; 12():510. PubMed ID: 23146383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
    Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
    Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
    Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA2 carriers with male breast cancer show elevated tumour methylation.
    Deb S; Gorringe KL; Pang JB; Byrne DJ; Takano EA; ; Dobrovic A; Fox SB
    BMC Cancer; 2017 Sep; 17(1):641. PubMed ID: 28893223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
    Fostira F; Saloustros E; Apostolou P; Vagena A; Kalfakakou D; Mauri D; Tryfonopoulos D; Georgoulias V; Yannoukakos D; Fountzilas G; Konstantopoulou I
    Breast Cancer Res Treat; 2018 May; 169(1):105-113. PubMed ID: 29335925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.
    Biesma HD; Schouten PC; Lacle MM; Sanders J; Brugman W; Kerkhoven R; Mandjes I; van der Groep P; van Diest PJ; Linn SC
    Genes Chromosomes Cancer; 2015 Dec; 54(12):734-44. PubMed ID: 26355282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
    Colombo M; Giarola M; Mariani L; Ripamonti CB; De Benedetti V; Sardella M; Losa M; Manoukian S; Peissel B; Pierotti MA; Pilotti S; Radice P
    Mod Pathol; 2008 Oct; 21(10):1262-70. PubMed ID: 18327210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
    Blanco A; Graña B; Fachal L; Santamariña M; Cameselle-Teijeiro J; Ruíz-Ponte C; Carracedo A; Vega A
    Clin Genet; 2010 Feb; 77(2):193-6. PubMed ID: 19930417
    [No Abstract]   [Full Text] [Related]  

  • 13. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
    Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
    Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy.
    Ottini L; Rizzolo P; Zanna I; Falchetti M; Masala G; Ceccarelli K; Vezzosi V; Gulino A; Giannini G; Bianchi S; Sera F; Palli D
    Breast Cancer Res Treat; 2009 Aug; 116(3):577-86. PubMed ID: 18819001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
    Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
    PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer predisposition syndromes.
    Hemel D; Domchek SM
    Hematol Oncol Clin North Am; 2010 Oct; 24(5):799-814. PubMed ID: 20816575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing in familial breast cancer patients from Lebanon.
    Jalkh N; Chouery E; Haidar Z; Khater C; Atallah D; Ali H; Marafie MJ; Al-Mulla MR; Al-Mulla F; Megarbane A
    BMC Med Genomics; 2017 Feb; 10(1):8. PubMed ID: 28202063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.